Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004410 | 0.91 | NR1H2 (0.36) | MRGPRX4ALOX5APTLR8NR1H2NR1H3 | |
| SCHEMBL18004323 | 0.91 | ALOX5AP (0.42) | ALOX5APTLR8NR1H2NR1H3TACR1 | |
| SCHEMBL18004430 | 0.88 | SMN1; SMN2 (0.36) | MRGPRX4ALOX5APNR1H2NR1H3KMT2A | |
| SCHEMBL18006203 | 0.86 | ALOX5AP (0.41) | ALOX5APTLR8NR1H2 | |
| SCHEMBL18004165 | 0.85 | NR1H2 (0.39) | MRGPRX4ALOX5APNR1H2NR1H3 | |
| SCHEMBL18004448 | 0.85 | NR1H2 (0.36) | MRGPRX4ALOX5APNR1H2KMT2A | |
| SCHEMBL18006172 | 0.85 | INPPL1 (0.43) | ALOX5APNR1H2KMT2A | |
| SCHEMBL18004407 | 0.84 | MAOB (0.39) | ALOX5APNR1H2NR1H3 | |
| SCHEMBL18004444 | 0.84 | GRIN1 (0.37) | ALOX5AP | |
| SCHEMBL18006186 | 0.84 | CNR2 (0.37) | NR1H2NR1H3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MRGPRX4 4062/4885ALOX5AP 3601/4885TLR8 4399/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MRGPRX4 4062/4885ALOX5AP 3601/4885TLR8 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.